Amelia Virtual Care Merges with XRHealth to Grow in Virtual Reality

New corporate operation in the health sector. Amelia Virtual Care and XRHealth have announced their merger, to create “the largest virtual reality therapeutic deep-tech platform,” as announced by both companies at the Trofeu Conde de Godó facilities in Barcelona.

The operation has been led by Asabys Partners, one of Amelia’s main investors from her Sabadell Asabys fund. In the beginning, Amelia had the support of BStartup10 from Banco Sabadell and Caixa Capital Risc, and later Sabadell Venture Capital from Banco Sabadell, Endra, and CG Ventures, among others, joined its shareholding.

The objective of the merger is that “the combination of the two businesses generates significant income in the coming months, surpassing other platforms and becoming the leading therapeutic solution in the augmented reality market,” according to both entities.

The joint platform will be used by more than 2,500 doctors worldwide and will perform more than 500,000 virtual reality treatments on around 25,000 patients before the end of 2023.

If you want to find more details about the merger between Amelia Virtual Care and XRHealth, and to read the most important business news of the day, download for free our companion app. The Born2Invest mobile, available for both Android and iOS devices, will bring you the most important market updates, so you can stay informed.

Amelia Virtual Care performs more than 500,000 virtual reality treatments annually

XRHealth offers a comprehensive therapeutic care solution that allows patients to receive treatment from home through augmented reality. Among the main diseases that the company treats are Parkinson’s, multiple sclerosis, stroke rehabilitation, and fibromyalgia.

Amelia Virtual Care offers virtual reality software for mental health professionals with more than 140 virtual environments, providing clinicians with access to exposure tools and systematic desensitization techniques. The solution is already offered in both centers in Europe and the United States.

“At a time when medical professionals are embracing virtual reality as a tool to deliver quality care, we seek to deliver compelling experiences for patients,” says Xavier Palomer, founder and president of Amelia.

For his part, Eran Orr, founder and CEO of XRHealth, added that “now that the industry is maturing, the time has come to introduce our technology in hospitals and clinics.”

In 2019, Amelia Virtual Care closed a round of €6 million led by Sabadell Asabys and Caixa Capital Risc. This investment has allowed it to develop technology and consolidate its presence in Europe and the United States. In 2022, the technology company raised seven million euros more from Endra, an international fund managed from London.

__

(Featured image by  Bermix Studio via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.